Kyverna Therapeutics, Inc, based in Emeryville, CA, is a patient-centered, clinical-stage biopharmaceutical company specializing in developing cell therapies for autoimmune diseases. The company's mission is to provide life-changing medicines for patients affected by autoimmune disorders by harnessing the curative potential of cell therapy. Kyverna is at the forefront of a new era in CAR T-cell therapy, pioneering a durable disease-clearing approach that targets deep B cell depletion, immune system reset, and long-term remission in autoimmune conditions. The company's pipeline includes next-generation CAR T-cell therapies in autologous and allogeneic formats, tailored to combat B cell-driven autoimmune diseases like lupus nephritis, multiple sclerosis, myasthenia gravis, stiff person syndrome, and systemic sclerosis. With a patient-centric focus, Kyverna is actively conducting clinical trials in multiple autoimmune diseases globally, offering a promising avenue for patients seeking innovative treatment options beyond conventional therapies. By leveraging the success of CAR T-cell therapies in hematological malignancies, Kyverna aims to deliver therapeutic benefits that can potentially change the landscape of autoimmune disease treatment. Generated from the website content